TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01041963
Drug: Enalapril
Normalized name: Enalapril
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with hypertension will take 20-40mg enalapril per day, antihypertensive agents other than ACE inhibitors and ARBs and spironolactone will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
Study: NCT01041963
Drug: Enalapril plus Losartan
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with hypertension will take 20-40mg enalapril plus 25-50mg losartan per day, antihypertensive agents other than ACE inhibitors and ARBs and spironolactone will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
Study: NCT00451633
Drug: E2007
Normalized name: Edoxaban
DrugBank: Edoxaban (DB09075)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01069900
Drug: Moxifloxacin (Avelox, BAY12-8039)
Normalized name: moxifloxacin Injection [Avelox]
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For subjects 12 to less than (\<) 18 years of age and weighing at least 45 kilograms (kg), the dose of moxifloxacin will be 400 milligrams (mg), once daily (OD). Subjects 12 to \< 18 years of age and weighing less than 45 kg, the dose of moxifloxacin will be 4 mg/kg twice daily (BID), every 12 hours (q12h), not exceeding 400 mg/day. Subjects 6 to \< 12 years of age the dose of moxifloxacin will be 4mg/kg, q12h, not exceeding 400 mg/day. Subjects 2 to less than 6 years of age the dose of moxifloxacin will be 5mg/kg, q12h, not exceeding 400 mg/day. Subjects 3 months to less than 2 years of age the dose of moxifloxacin will be 6mg/kg q12h IV, not exceeding 400 mg/day. Subjects who were switched from IV to PO therapy, 400 mg or 50 mg moxifloxacin tablets were provided.
Study: NCT01069900
Drug: Ertapenem
Normalized name: Ertapenem
DrugBank: Ertapenem (DB00303)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: For subjects 13 to \<18 years of age, the dosage of ertapenem was 1 gram (g) OD. For subjects 3 months to \< 13 years of age, the dosage was 15 mg/kg q12h not to exceed 1 g/day.
Study: NCT01069900
Drug: Amoxicillin/Clavulanate
Normalized name: AMOXICILLIN/CLAVULANATE
DrugBank: Clavulanic acid (DB00766)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects 2 years to \< 18 years of age who were switched from IV to PO therapy receive amoxicillin/clavulanate suspension. The dosage of clavulanate was 3.2 mg/kg q12h. (maximum dose of clavulanate was 125 mg q12h). The dosage of amoxicillin was 22.5 mg q12h (a maximum dose of 875 mg amoxicillin q12h must not be exceeded).
Study: NCT01069900
Drug: Moxifloxacin placebo
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sterile 0.9% sodium chloride solution intended for IV use was used as the placebo for IV moxifloxacin. Tablets containing inactive ingredients were used as the placebo for PO moxifloxacin 400 mg and 50 mg tablets.
Study: NCT01069900
Drug: Ertapenem placebo
DrugBank: Ertapenem (DB00303)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sterile 0.9% sodium chloride solution intended for IV use was used as the placebo for IV ertapenem.
Study: NCT01069900
Drug: Amoxicillin/Clavulanate placebo
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Suspension containing inactive ingredients was used as the placebo for PO amoxicillin/clavulanate suspension.
Study: NCT02642315
Drug: Horizant
Normalized name: Horizant
DrugBank: Gabapentin enacarbil (DB08872)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phase1: During phase 1 therapy, Horizant will be added on as an adjunct to all subjects taking part in the study along with stable dose of their current dopaminergic (DA) agent and both medication will be continued for a total period of 90 days from day 0 to day 90. Subjects will be evaluated for three visits (days 0, 30 and 90) during Phase I.~Phase 2: At the 90th day follow-up visit, with initiation of phase 2 therapy, all subjects will be tapered off (by 50% reduction in dose each week) of their current dopaminergic agents while maintaining the same dose of Horizant and will be on Horizant monotherapy. All subjects will be evaluated for additional three clinic visits (days 120, 180, 360).
Study: NCT01888302
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01888302
Drug: Gemcitabine Hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01888302
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT02631590
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin administered once as intravenous (IV) infusion over 60 minutes. Treatment is on Days 1 and 8 every 21 days.
Study: NCT02631590
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine administered as 30-min IV infusion. Treatment is on Days 1 and 8 every 21 days.
Study: NCT02631590
Drug: Copanlisib
Normalized name: Copanlisib
DrugBank: Copanlisib (DB12483)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental Drug: Copanlisib administered as an IV over 60-minutes beginning 1 hour after completing gemcitabine infusion. Treatment is on Days 1 and 8 every 21 days.
Study: NCT03052608
Drug: Lorlatinib
Normalized name: LORLATINIB
DrugBank: Lorlatinib (DB12130)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ALK-positive NSCL treatment
Study: NCT03052608
Drug: Crizotinib
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ALK-positive NSCL treatment
Study: NCT02859571
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01550224
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: An alkylating agent administered for induction per standard of care at 200 mg/m²/day for 7days.
Study: NCT01550224
Drug: Vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A synthetic hydroxamic acid derivative with antineoplastic activity administered for both groups at 500 mg orally 3 times daily for 3 days prior to Temozolomide 200 mg/m²/day.
Study: NCT01685502
Drug: Glucobay ODT (Acarbose, BAYG5421)
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients treated with Glucobay OD under practical manner
Study: NCT02383212
Drug: Cemiplimab
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02383212
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02383212
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02383212
Drug: GM-CSF
Normalized name: GM-CSF
DrugBank: Regramostim (DB05386)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02383212
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02383212
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00214890
Drug: Tenofovir
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300 mg once daily
Study: NCT00214890
Drug: Abacavir
Normalized name: Abacavir
DrugBank: Abacavir (DB01048)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 600 mg once daily
Study: NCT00489593
Drug: Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5 mg by mouth (PO) Daily x 28 days, increasing about every 3-14 days in increments of 2.5-5 mg until the designated dose for that cohort is reached.
Study: NCT01772316
Drug: tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 162 mg subcutaneously weekly or every two weeks, 96 weeks
Study: NCT01647217
Drug: Terpinen-4-ol
Normalized name: Terpinen-4-ol
DrugBank: Terpinen-4-ol (DB12816)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lid scrub once or twice per day for one month.
Study: NCT02225002
Drug: CP-870,893
DrugBank: Selicrelumab (DB14958)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01936870
Drug: Fesoterodine (Toviaz)
Normalized name: fesoterodine Extended Release Oral Tablet [Toviaz]
DrugBank: Fesoterodine (DB06702)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fesoterodine 4 mg or 8 mg orally. Toviaz will be dosed according to labeling. The administration and duration of therapy will be determined by the treating physician to meet the patient's needs for treatment.
Study: NCT03762317
Drug: Clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: clonidine will be given at 12 mcg/kg/d to the experimental arm in addition to oral morphine
Study: NCT02844309
Drug: Thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: thalidomide 50-150 mg per night
Study: NCT00766662
Drug: Sulfadoxine pyrimethamine
Normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04469764
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT04469764
Drug: Anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT04469764
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00719472
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: During Cycle 1 rituximab was administered at an initial rate of 50 mg/hour. In the absence of infusion toxicity during Cycle 1, the infusion rate was escalated by 50 mg/h increments every 30 minutes to a maximum rate of 400 mg/hour. In case of infusion-related reactions, the infusion was interrupted or the infusion rate reduced. In case of Grade 3/4 infusion reactions, the rituximab infusion was discontinued and medical treatment provided. If the rituximab infusion in Cycle 1 was tolerated without a serious adverse event (AE) or Grade 3/4 infusion-related AE, as judged by the investigator, infusions in Cycle 2 onwards were administered as follows: 20% of the total dose was given over 30 minutes and the remaining 80% of the dose was given over the next 60 minutes, for a total infusion time of 90 minutes. Commercial preparations of rituximab were used.
Study: NCT00719472
Drug: CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone)
Normalized name: ethanol
DrugBank: Trichophyton mentagrophytes (DB10446)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercial preparations of CHOP were used. Prednisone was administered prior to rituximab infusion.
Study: NCT00719472
Drug: CVP (cyclophosphamide, vincristine, prednisone)
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercial preparations of CVP were used. Prednisone was administered prior to rituximab infusion.
Study: NCT00719472
Drug: Analgesic/antipyretic and antihistamine drugs
DrugBank: Histamine (DB05381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An analgesic/antipyretic (eg, acetaminophen) and an antihistamine (eg, diphenhydramine) were administered 30 minutes before each infusion of rituximab.
Study: NCT01090661
Drug: mipomersen sodium
Normalized name: Mipomersen Sodium
DrugBank: Mipomersen (DB05528)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg of mipomersen intravenous (IV) (single dose)
Study: NCT01090661
Drug: mipomersen sodium
Normalized name: Mipomersen Sodium
DrugBank: Mipomersen (DB05528)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg of mipomersen subcutaneous (SC) (single dose)
Study: NCT01090661
Drug: moxifloxacin hydrochloride (Avelox®)
Normalized name: moxifloxacin Injection [Avelox]
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg of moxifloxacin intravenous (IV) single dose
Study: NCT04043858
Drug: Midodrine 2.5 mg tab
DrugBank: Midodrine (DB00211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients receive an oral daily dose of 2.5 mg midodrine if age 7-12 years and receive 2.5 mg twice daily of more than 12 years
Study: NCT02695563
Drug: Lactoferrin
Normalized name: Lactoferrin
DrugBank: Lactoferrin (DB16555)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00475696
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00229567
Drug: Lidocaine infusion plus ketamine injection
Normalized name: ketamine Injectable Solution
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03673124
Drug: Ribociclib
Normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 600 mg by mouth daily for 21 days followed by 7 days off treatment
Study: NCT02198404
Drug: sedation with propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: induction with propofol at 20mg/kg/h. Then, when the patient is sleeping, dosage is decreased to 6 mg/kg/h
Study: NCT03673124
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5 mg by mouth daily
Study: NCT00958906
Drug: Infliximab (intravitreal, 2.0mg/0.05ml)
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: One injection of intravitreal infliximab (2.0mg/0.05ml).
Study: NCT03396601
Drug: Ketamine Hydrochloride
Normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketamine HCl will be infused intravenously at a dose of 0.5 mg/kg over 40 minutes
Study: NCT00104923
Drug: fenretinide
Normalized name: FENRETINIDE
DrugBank: Fenretinide (DB05076)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current dose level as an IV continuous infusion via central line over 5 days. Cycle is repeated every 3 weeks for up to 6 cycles
Study: NCT00372593
Drug: asparaginase
Normalized name: Asparaginase
DrugBank: Asparaginase Escherichia coli (DB00023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given intramuscularly
Study: NCT00372593
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00372593
Drug: daunorubicin hydrochloride
Normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV over 6 hours
Study: NCT00372593
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV over 1-4 hours
Study: NCT00372593
Drug: gemtuzumab ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV over 2 hours
Study: NCT00372593
Drug: mitoxantrone hydrochloride
Normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV over 1 hour
Study: NCT00473213
Drug: Interferon Beta 1
Normalized name: Interferon beta 1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00946621
Drug: Ramipril 10 mg Capsule (Sandoz)
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00946621
Drug: Altace (Ramipril) 10 mg Capsule (Aventis Pharmaceutical)
Normalized name: ramipril 10 MG [Altace]
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00030732
Drug: Gemcitabine alone
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine alone
Study: NCT02212951
Drug: Humulin R U-500
Normalized name: Humulin R U-500 500unit/mL Solution for Injection
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04129008
Drug: Indobufen and aspirin mimetic
Normalized name: indobufen
DrugBank: Indobufen (DB12545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 1 to 84±7: The first time: indobufen 100mg + aspirin mimetic; The second time: indobufen 100mg
Study: NCT04129008
Drug: Aspirin and indobufen mimetic
Normalized name: indobufen
DrugBank: Indobufen (DB12545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 1 to 84±7: The first time : aspirin 100mg+ indobufen mimetic; The second time: indobufen mimetic
Study: NCT01092546
Drug: [18F]Flutemetamol
DrugBank: Flutemetamol (18F) (DB09151)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All subjects will receive an IV dose of \[18F\]flutemetamol (less than 10 mg flutemetamol). The nominal activity of a single administration of \[18F\]flutemetamol will be 185 MBq.
Study: NCT02578706
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel 75mg
Study: NCT02578706
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 81 mg
Study: NCT00408200
Drug: propafenone; flecainide; sotalol; dofetilide
DrugBank: Dofetilide (DB00204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Above drugs prescribed per established guidelines for treatment of AF
Study: NCT00350415
Drug: Mesalamine
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Asacol 400g/day (400 mg tablet), oral, for 6 weeks~OR~Asacol 4,8 g/day (800 mg table), oral, for 6 weeks
Study: NCT02961829
Drug: Maraviroc
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: antiretroviral intensification
Study: NCT02961829
Drug: Dolutegravir
Normalized name: Dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: antiretroviral intensification
Study: NCT02961829
Drug: Auranofin
Normalized name: Auranofin
DrugBank: Auranofin (DB00995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: purging
Study: NCT00087867
Drug: SCIO-469 and bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In addition to SCIO-469, patients with disease progression will receive bortesomib 1.0 mg/m2 intravenously as a bolus injection on Days 1, 4, 8, and 11 of a 21-day cycle, followed by a 10-day rest period
Study: NCT00622440
Drug: AIJP (Arnebia Indigo Jade Pearl)
Normalized name: indigo
DrugBank: Indigo (DB16862)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will administer their own treatment using 1/4 teaspoon of the cream twice daily for 48 weeks.
Study: NCT04203186
Drug: atovaquone-proguanil
Normalized name: atovaquone-proguanil
DrugBank: Atovaquone (DB01117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Malaria standard treatment regimen
Study: NCT00042315
Drug: tariquidar + vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00042315
Drug: placebo + vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00775827
Drug: fenofibrate 160 mg tablets
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003758
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04455815
Drug: Camostat
Normalized name: camostat
DrugBank: Camostat (DB13729)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient to receive treatment with camostat tablets, 200mg four times daily (qds) for 14 days.
Study: NCT00003758
Drug: idarubicin
Normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05125588
Drug: Movalis 15 mg tablets (Boehringer Ingelheim Ellas A.E., Greece)
Normalized name: Ella
DrugBank: Ulipristal (DB08867)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: One tablet was administered orally and swallowed at once, without chewing, by study volunteers, followed by 200 ml of water, under fasting condition (after preliminary nocturnal fasting for 12 hours) in the morning at 8:00 hours on Day I Period I and Period II of the study.
Study: NCT03565094
Drug: Lu AF28996 solution
Normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution (0.1-0.2 mg/mL)~Following each cohort, a dosing conference will be held where tolerability, safety and preliminary PK results from the previous cohorts will be reviewed before deciding on the next doses
Study: NCT03565094
Drug: Lu AF28996 capsule
Normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: hard capsule orally QD: one dose lower than the highest dose level in part A
Study: NCT00419952
Drug: Budesonide/formoterol (SYMBICORT) pMDI
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Symbicort pMDI 160/4.5 ug x 2 actuations twice daily (BID)
Study: NCT00419952
Drug: Budesonide HFA pMDI
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide HFA pMDI 160 ug x 2 actuations BID
Study: NCT03096249
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Syntocinon nasal spray: single dose of 24IU (3 puffs of 4IU per nostril)
Study: NCT02254629
Drug: Probiotic Clostridium Butyricum
Normalized name: Clostridium tetani
DrugBank: Clostridium tetani (DB09876)
Approvals — FDA: no, EMA: no, PMDA: no
Description: probiotic:2 tablets/ times, 3 times / day for 2 weeks
Study: NCT02254629
Drug: Laxative Polyethylene Glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: laxative：2000 ml.
Study: NCT03132610
Drug: andrographolide sulfonate
Normalized name: Dimethyl sulfone
DrugBank: Andrographolide (DB05767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Therapy+Xiyanping injection
Study: NCT03132610
Drug: andrographolide sulfonate simulation
Normalized name: Dimethyl sulfone
DrugBank: Andrographolide (DB05767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Therapy+Xiyanping injection simulation
Study: NCT01082068
Drug: XL765 (SAR245409)
Normalized name: XL765
DrugBank: XL765 (DB05241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: given orally twice daily as capsules
Study: NCT01082068
Drug: letrozole (Femara)
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: given orally once daily as tablets
Study: NCT01042106
Drug: DSP-8658
Normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascending doses of DSP-8658 - 2.5, 10, 20, 40 mg orally once daily